Immunization

The FDA’s final decision is expected by a Prescription Drug User Fee Act goal date in August 2023.

From 2017 to 2021, Australia did not experience a large increase in infections of serotype 19A across all ethnic and age groups, unlike New Zealand.

Findings suggest that mice derived from and breastfed by immunized mothers were capable of producing anti- pneumococcal surface protein A (PspA) specific antibodies, despite having no direct exposure to PspA.

Nanoparticles could improve the solubility of drugs, aid in treatment escape from the immune system, and increase the half-life of drugs in the circulatory system against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus.

PCV10 protection is likely to have reduced the incidence of pneumococcal disease among all ages by between 48% and 66%.

Investigators of the phase 2 study also found a comparable reactogenicity to the individual influenza and COVID-19 vaccines from Novavax or authorized vaccine comparators.

The 2022-2023 COVID-19 season did not have a significant surge of COVID-19 like it did early on in the COVID-19 pandemic.

Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.

The study shed light on the importance of the source of vaccine information and other factors that prevent lifesaving vaccination.

It is possible that the pandemic had a positive impact on influenza vaccination rates.

Study sheds light on the importance of the source of vaccine information and other factors that prevent lifesaving influenza or pneumococcal vaccination.

Misinformation on YouTube promotes women wiping front to back as a non-evidence-based hygiene practice to prevent urinary tract infection.

Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Neutralizing monoclonal antibody therapies found to improve outcomes for unvaccinated and nonhospital patients at high risk of poor outcome for SARS-CoV-2.

The BCG vaccine was more likely to cause symptomatic or severe COVID-19 in patients that had a preexisting condition, such as heart disease, by 6 months.

Analysis shows that the ratio of neutralizing antibody geometric mean titers in adolescents compared with young adults was 1.5 after vaccination with NVX-CoV2373.

Prevnar 20 is a next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13.

The analysis, published in Nature Communications, demonstrates glycan trimming also keeps the antibody response away from immunodominant glucan holes and patches.

Study results indicate a decrease in the exclusion of older adults but no significant change for individuals who are immunocompromised.

A 10% increase in the proportion of adults aged 50 years or older was associated with a 1.2% increase in pneumococcal vaccination coverage.

VAX-24 is designed to prevent invasive pneumococcal disease and pneumonia, which can be most serious for infants, young children, older adults, and those with immune deficiencies or some chronic health conditions.

Building strong, trusting relationships helps combat hesitancy, creating healthier communities.

Agency updates emergency use authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccinations, which are no longer authorized for used in the United States.

Atypical respiratory syncytial virus epidemics may continue, and testing patients for multiple respiratory pathogens when indicated might be necessary.

Respiratory syncytial virus (RSV) vaccine demonstrated efficacy of 66.7% in reducing RSV-associated lower respiratory tract illness with at least 2 signs or symptoms in older adults.